Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Liverpool Hospital, Liverpool

Royal Brisbane and Women's Hospital, Brisbane

Griffith University, School of Medicine, Southport

Columbia University Medical Center-The Neurological Institute of New York, New York

Dent Neurologic Institute, Amherst

University of Rochester Medical Center - URMC, Rochester

MS Center of Greater Washington, Vienna

PMG Research of Piedmont Healthcare, Mooresville

Premier Neurology P.C., Greer

Neurology Associates, PA-Maitland, Maitland

University of South Florida, Morsani College of Medicine, Tampa

Advanced Neurosciences Institute ANI - Franklin, Franklin

Vanderbilt Comprehensive Multiple Sclerosis Center, Nashville

Fort Wayne Neurological Center, Fort Wayne

Medical College of Wisconsin, Milwaukee

Washington University in St. Louis, St Louis

University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center, Kansas City

Ochsner Clinic Foundation, New Orleans

The University of Texas Health Science Center at Houston, Houston

University of Colorado, Aurora

Advanced Neurology, Fort Collins

Kaiser Permanente MS Clinic Los Angeles, Los Angeles

University of California, San Diego, La Jolla

University of California San Francisco, San Francisco

Stanford University, Palo Alto

Inland Northwest Research LLC, Spokane

Dragonfly Research, Wellesley

University of Pennsylvania, Philadelphia

Fraser Health Multiple Sclerosis Clinic, Burnaby

Unity Health Toronto/St. Michael's Hospital, Toronto

Recherche Sepmus Inc., Greenfield Park